[{"id":"679fafe7-f90a-4324-b109-03c540d1aab2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04231747","created_at":"2021-01-18T20:35:10.173Z","updated_at":"2024-07-02T16:35:02.622Z","phase":"Phase 1","brief_title":"A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04231747","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • zolacaptagene autoleucel (BMS-986353)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 05/21/2020","start_date":" 05/21/2020","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2024-05-20"}]